FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2467097643> ?p ?o ?g. }

• W2467097643 endingPage "579" @default.
• W2467097643 startingPage "569" @default.
• W2467097643 abstract "To date more than 20 glycation products were identified, of which ~15 in the insoluble human skin collagen fraction. The goal of this review is to streamline 30 years of research and ask a set of important questions: in Type 1 diabetes which glycation products correlate best with 1) past mean glycemia 2) reversibility with improved glycemic control, 2) cross-sectional severity of retinopathy, nephropathy and neuropathy and 3) the future long-term risk of progression of micro- and subclinical macrovascular disease. The trio of glycemia related glycation markers furosine (FUR)/fructose-lysine (FL), glucosepane and methylglyoxal hydroimidazolone (MG-H1) emerges as extraordinarily strong predictors of existing and future microvascular disease progression risk despite adjustment for both past and prospective A1c levels. X(2) values are up to 25.1, p values generally less than 0.0001, and significance remains after adjustment for various factors such as A1c, former treatment group, log albumin excretion rate, abnormal autonomic nerve function and LDL levels at baseline. In contrast, subclinical cardiovascular progression is more weakly correlated with AGEs/glycemia with X(2) values < 5.0 and p values generally < 0.05 after all adjustments. Except for future carotid intima-media thickness, which correlates with total AGE burden (MG-H1, pentosidine, fluorophore LW-1 and decreased collagen solubility), adjusted FUR and Collagen Fluorescence (CLF) are the strongest markers for future coronary artery calcium deposition, while cardiac hypertrophy is associated with LW-1 and CLF adjusted for A1c. We conclude that a robust clinical skin biopsy AGE risk panel for microvascular disease should include at least FUR/FL, glucosepane and MG-H1, while a macrovascular disease risk panel should include at least FL/FUR, MG-H1, LW-1 and CLF." @default.
• W2467097643 created "2016-07-22" @default.
• W2467097643 creator A5029026718 @default.
• W2467097643 creator A5048439423 @default.
• W2467097643 creator A5071915821 @default.
• W2467097643 date "2016-06-25" @default.
• W2467097643 modified "2023-10-18" @default.
• W2467097643 title "The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes" @default.
• W2467097643 cites W1676536 @default.
• W2467097643 cites W1965220977 @default.
• W2467097643 cites W1968003131 @default.
• W2467097643 cites W1982698379 @default.
• W2467097643 cites W1993736540 @default.
• W2467097643 cites W1994051814 @default.
• W2467097643 cites W2005793050 @default.
• W2467097643 cites W2006672342 @default.
• W2467097643 cites W2021159879 @default.
• W2467097643 cites W2049385216 @default.
• W2467097643 cites W2052681712 @default.
• W2467097643 cites W2054221638 @default.
• W2467097643 cites W2058786800 @default.
• W2467097643 cites W2066268043 @default.
• W2467097643 cites W2070979227 @default.
• W2467097643 cites W2082227293 @default.
• W2467097643 cites W2086321305 @default.
• W2467097643 cites W2097899363 @default.
• W2467097643 cites W2114837987 @default.
• W2467097643 cites W2122907952 @default.
• W2467097643 cites W2123142490 @default.
• W2467097643 cites W2123946565 @default.
• W2467097643 cites W2124098523 @default.
• W2467097643 cites W2132095884 @default.
• W2467097643 cites W2139163490 @default.
• W2467097643 cites W2139912326 @default.
• W2467097643 cites W2147602249 @default.
• W2467097643 cites W2153558667 @default.
• W2467097643 cites W2153605160 @default.
• W2467097643 cites W2160635731 @default.
• W2467097643 cites W2162869854 @default.
• W2467097643 cites W2166212677 @default.
• W2467097643 cites W2169095364 @default.
• W2467097643 cites W2172157568 @default.
• W2467097643 cites W2257922032 @default.
• W2467097643 cites W2337292567 @default.
• W2467097643 cites W2414874586 @default.
• W2467097643 cites W2432578221 @default.
• W2467097643 cites W2735325912 @default.
• W2467097643 cites W2769264260 @default.
• W2467097643 doi "https://doi.org/10.1007/s10719-016-9702-2" @default.
• W2467097643 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5080659" @default.
• W2467097643 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27342131" @default.
• W2467097643 hasPublicationYear "2016" @default.
• W2467097643 type Work @default.
• W2467097643 sameAs 2467097643 @default.
• W2467097643 citedByCount "24" @default.
• W2467097643 countsByYear W24670976432017 @default.
• W2467097643 countsByYear W24670976432018 @default.
• W2467097643 countsByYear W24670976432019 @default.
• W2467097643 countsByYear W24670976432020 @default.
• W2467097643 countsByYear W24670976432021 @default.
• W2467097643 countsByYear W24670976432022 @default.
• W2467097643 crossrefType "journal-article" @default.
• W2467097643 hasAuthorship W2467097643A5029026718 @default.
• W2467097643 hasAuthorship W2467097643A5048439423 @default.
• W2467097643 hasAuthorship W2467097643A5071915821 @default.
• W2467097643 hasBestOaLocation W24670976432 @default.
• W2467097643 hasConcept C113280763 @default.
• W2467097643 hasConcept C126322002 @default.
• W2467097643 hasConcept C134018914 @default.
• W2467097643 hasConcept C147990577 @default.
• W2467097643 hasConcept C164705383 @default.
• W2467097643 hasConcept C2777180221 @default.
• W2467097643 hasConcept C2778848681 @default.
• W2467097643 hasConcept C2780473172 @default.
• W2467097643 hasConcept C2780758796 @default.
• W2467097643 hasConcept C555293320 @default.
• W2467097643 hasConcept C71924100 @default.
• W2467097643 hasConcept C90924648 @default.
• W2467097643 hasConceptScore W2467097643C113280763 @default.
• W2467097643 hasConceptScore W2467097643C126322002 @default.
• W2467097643 hasConceptScore W2467097643C134018914 @default.
• W2467097643 hasConceptScore W2467097643C147990577 @default.
• W2467097643 hasConceptScore W2467097643C164705383 @default.
• W2467097643 hasConceptScore W2467097643C2777180221 @default.
• W2467097643 hasConceptScore W2467097643C2778848681 @default.
• W2467097643 hasConceptScore W2467097643C2780473172 @default.
• W2467097643 hasConceptScore W2467097643C2780758796 @default.
• W2467097643 hasConceptScore W2467097643C555293320 @default.
• W2467097643 hasConceptScore W2467097643C71924100 @default.
• W2467097643 hasConceptScore W2467097643C90924648 @default.
• W2467097643 hasFunder F4320306172 @default.
• W2467097643 hasFunder F4320337350 @default.
• W2467097643 hasFunder F4320337357 @default.
• W2467097643 hasIssue "4" @default.
• W2467097643 hasLocation W24670976431 @default.
• W2467097643 hasLocation W24670976432 @default.
• W2467097643 hasLocation W24670976433 @default.
• W2467097643 hasLocation W24670976434 @default.

• next